JP2018531014A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531014A5
JP2018531014A5 JP2018518999A JP2018518999A JP2018531014A5 JP 2018531014 A5 JP2018531014 A5 JP 2018531014A5 JP 2018518999 A JP2018518999 A JP 2018518999A JP 2018518999 A JP2018518999 A JP 2018518999A JP 2018531014 A5 JP2018531014 A5 JP 2018531014A5
Authority
JP
Japan
Prior art keywords
human
domain
car
intracellular
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018518999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531014A (ja
JP2018531014A6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056262 external-priority patent/WO2017066122A1/en
Publication of JP2018531014A publication Critical patent/JP2018531014A/ja
Publication of JP2018531014A6 publication Critical patent/JP2018531014A6/ja
Publication of JP2018531014A5 publication Critical patent/JP2018531014A5/ja
Pending legal-status Critical Current

Links

JP2018518999A 2015-10-15 2016-10-10 抗cd30キメラ抗原受容体 Pending JP2018531014A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241896P 2015-10-15 2015-10-15
US62/241,896 2015-10-15
PCT/US2016/056262 WO2017066122A1 (en) 2015-10-15 2016-10-10 Anti-cd30 chimeric antigen receptors

Publications (3)

Publication Number Publication Date
JP2018531014A JP2018531014A (ja) 2018-10-25
JP2018531014A6 JP2018531014A6 (ja) 2018-12-13
JP2018531014A5 true JP2018531014A5 (enExample) 2019-11-21

Family

ID=57178532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518999A Pending JP2018531014A (ja) 2015-10-15 2016-10-10 抗cd30キメラ抗原受容体

Country Status (11)

Country Link
US (1) US10815301B2 (enExample)
EP (1) EP3362476B1 (enExample)
JP (1) JP2018531014A (enExample)
KR (1) KR20180057723A (enExample)
CN (1) CN108137703A (enExample)
AU (1) AU2016338747B2 (enExample)
BR (1) BR112018006995A2 (enExample)
CA (1) CA3002000A1 (enExample)
IL (1) IL258527A (enExample)
MX (1) MX2018004503A (enExample)
WO (1) WO2017066122A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2836743T3 (es) * 2014-06-02 2021-06-28 Us Health Receptores de antígeno quiméricos que seleccionan como diana CD-19
CN110662771B (zh) * 2018-02-01 2023-07-28 南京驯鹿生物技术股份有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
IT201800003464A1 (it) * 2018-03-13 2019-09-13 Ospedale Pediatrico Bambino Gesu Cellule T CAR-CD30 per il trattamento di tumori CD30+
WO2020009868A1 (en) 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
WO2020061048A1 (en) * 2018-09-17 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
CA3155291A1 (en) 2018-09-24 2020-04-02 The Medical College Of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
EP3856778A1 (en) 2018-09-24 2021-08-04 The Medical College of Wisconsin, Inc. System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
WO2020085480A1 (ja) * 2018-10-26 2020-04-30 キッセイ薬品工業株式会社 高効率な遺伝子改変細胞の作製方法
WO2021019706A1 (ja) * 2019-07-31 2021-02-04 国立大学法人信州大学 Car発現免疫細胞を含む細胞集団の製造方法
CN110559430B (zh) * 2019-10-21 2023-07-11 江苏省肿瘤医院 一种抗淋巴瘤的car-t药物及其应用
CN110628823B (zh) * 2019-10-21 2022-12-27 江苏省肿瘤医院 一种cd30 car慢病毒表达载体及其制备方法和应用
CN113527507A (zh) * 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 靶向cd22的嵌合抗原受体及其制法和应用
WO2021221927A1 (en) * 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス,インコーポレイテッド プロテアーゼ活性化cd45ゲートcar
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
CN116964098A (zh) 2021-03-01 2023-10-27 南特生物公司 抗cd30单克隆抗体和嵌合抗原受体
KR102671409B1 (ko) 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
KR20230012129A (ko) 2021-07-14 2023-01-26 주식회사 이뮤노로지컬디자이닝랩 Cd30에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
US20250268940A1 (en) 2022-04-19 2025-08-28 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
EP4658298A1 (en) 2023-01-30 2025-12-10 Ludwig-Maximilians-Universität München, in Vertretung des Freistaates Bayern Anti-cd86 car expressing lymphocytes for targeted tumor therapy
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포
EP4674430A1 (en) 2024-07-01 2026-01-07 Universität zu Köln Edited cytotoxic cells with chimeric antigen receptors targeting cd30 for the treatment of infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
EP1471938A4 (en) * 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗cd30抗体
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US9598489B2 (en) * 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP6285553B2 (ja) * 2013-08-26 2018-02-28 インノバイオファーム リミテッド 抗cd30キメラ抗原受容体およびその使用
CN105859890A (zh) * 2015-01-19 2016-08-17 西比曼生物科技(上海)有限公司 嵌合抗原受体及其基因和重组表达载体、工程化cd30靶向性的nkt细胞及其应用
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof

Similar Documents

Publication Publication Date Title
JP2019530431A5 (enExample)
JP2017508466A5 (enExample)
JP2023139070A5 (enExample)
JP2019527557A5 (enExample)
JP2016514462A5 (enExample)
RU2015117237A (ru) Химерные антигенные рецепторы м971
JP2021531004A5 (enExample)
RU2017121892A (ru) Клетка
JP2016538830A5 (enExample)
JP2017537627A5 (enExample)
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
JP2016514457A5 (enExample)
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2017500869A5 (enExample)
JP2016502512A5 (enExample)
JP2018505139A5 (enExample)
JP2019528769A5 (enExample)
JP2019519529A5 (enExample)
JP2020525032A5 (enExample)
JP2017513478A5 (enExample)
CN110582488A (zh) 具有增强功效的免疫效应细胞疗法
JP2018029594A5 (enExample)
RU2016138422A (ru) Химерный антигенный рецептор
JP2016508725A5 (enExample)
JP2017507917A5 (enExample)